The thing to know about Dyax is that the HAE indication for DX-88 is mostly beneficial to get the drug approved for human use. Once DX-88 is approved, it is available for off label indications like CABG, currently in phase II trials. If a couple surgeons see better outcomes with DX-88 in their solutions (and the trials are quite promising), the drug will become very popular very quickly regardless of what the on-label indications are.

this new drug that they are coming out with will most likely get accepted to distribute throughout the public. if it does, the prices will soar for the next few months. im not sure how the long term will do though.